Want to see HK:9989 full AI Analyst Report?
Total Valuation
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H has a market cap or net worth of HK$14.90B. The enterprise value is HK$5.25K.
Market CapHK$14.90B
Enterprise ValueHK$5.25K
Share Statistics
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H has 220,094,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding220,094,500
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s return on equity (ROE) is 0.03 and return on invested capital (ROIC) is 3.75%.
Return on Equity (ROE)0.03
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)3.75%
Return on Capital Employed (ROCE)0.05
Revenue Per Employee2.55M
Profits Per Employee159.37K
Employee Count2,150
Asset Turnover0.33
Inventory Turnover0.84
Valuation Ratios
The current PE Ratio of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H is 70.6. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s PEG ratio is -0.43.
PE Ratio70.6
PS Ratio1.25
PB Ratio0.57
Price to Fair Value0.57
Price to FCF4.31
Price to Operating Cash Flow8.70
PEG Ratio-0.43
Income Statement
In the last 12 months, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H had revenue of 5.48B and earned 349.49M in profits. Earnings per share was 0.24.
Revenue5.48B
Gross Profit1.74B
Operating Income635.97M
Pretax Income402.24M
Net Income349.49M
EBITDA846.59M
Earnings Per Share (EPS)0.24
Cash Flow
In the last 12 months, operating cash flow was 1.50B and capital expenditures -80.86M, giving a free cash flow of 1.42B billion.
Operating Cash Flow1.50B
Free Cash Flow1.42B
Free Cash Flow per Share6.45
Dividends & Yields
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H pays an annual dividend of HK$0.166, resulting in a dividend yield of 4.09%
Dividend Per ShareHK$0.166
Dividend Yield4.09%
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.97
52-Week Price Change-23.39%
50-Day Moving Average4.24
200-Day Moving Average4.60
Relative Strength Index (RSI)48.65
Average Volume (3m)620.85K
Important Dates
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H upcoming earnings date is Nov 4, 2026, TBA (Not Confirmed).
Last Earnings DateAug 28, 2026
Next Earnings DateNov 4, 2026
Ex-Dividend Date―
Financial Position
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H as a current ratio of 2.31, with Debt / Equity ratio of 24.53%
Current Ratio2.31
Quick Ratio1.19
Debt to Market Cap0.30
Net Debt to EBITDA0.90
Interest Coverage Ratio8.90
Taxes
In the past 12 months, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H has paid 59.60M in taxes.
Income Tax59.60M
Effective Tax Rate0.15
Enterprise Valuation
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H EV to EBITDA ratio is 9.01, with an EV/FCF ratio of 4.79.
EV to Sales1.39
EV to EBITDA9.01
EV to Free Cash Flow4.79
EV to Operating Cash Flow4.45
Balance Sheet
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H has HK$3.55B in cash and marketable securities with HK$2.89B in debt, giving a net cash position of HK$655.00M billion.
Cash & Marketable SecuritiesHK$3.55B
Total DebtHK$2.89B
Net CashHK$655.00M
Net Cash Per ShareHK$2.98
Tangible Book Value Per ShareHK$6.44
Margins
Gross margin is 33.81%, with operating margin of 11.61%, and net profit margin of 6.38%.
Gross Margin33.81%
Operating Margin11.61%
Pretax Margin7.34%
Net Profit Margin6.38%
EBITDA Margin15.45%
EBIT Margin8.65%
Analyst Forecast
The average price target for Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast3.10%
EPS Growth Forecast-46.64%